CanSino Biologics Inc. has received a drug registration certificate from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) for its ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, Menhycia.

• Approved Indication: Menhycia is a quadrivalent meningococcal conjugate vaccine designed to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W135.
• Current Use: The vaccine is approved in China for use in children aged 3 months to 6 years (83 months).
• International Expansion: The approval strengthens CanSinoBIO’s presence in South America as part of the company’s international expansion strategy.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.